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Objectives The aim of this study was to compare treatment effects of drug-eluting stents (DES) or coronary artery bypass
grafting (CABG) for left main coronary artery (LMCA) disease according to the complexity of atherosclerotic
disease burden.
Background Limited information is available on the relationships between the extent of coronary atherosclerosis and very
long-term outcomes of surgical or percutaneous LMCA revascularization.
Methods A total of 1,146 patients with unprotected LMCA disease who received DES (n  645) or underwent CABG
(n  501) were evaluated. The extent of atherosclerotic disease burden was measured using the SYNTAX (Syn-
ergy Between PCI With Taxus and Cardiac Surgery) score; a low-risk score was defined as 22, an intermediate-
risk score as 23 to 32, and a high-risk score as 33.
Results After multivariate adjustment with the inverse-probability-of-treatment weighting method, the 5-year risks for
death (6.1% for DES vs. 16.2% for CABG; hazard ratio [HR]: 0.52; 95% confidence interval [CI]: 0.21 to 1.28;
p  0.15) and the composite of death, Q-wave myocardial infarction, or stroke (6.4% vs. 16.2%; HR: 0.54; 95%
CI: 0.22 to 1.34; p  0.18) favored DES in patients with low-risk SYNTAX scores; in contrast, the 5-year risks for
death (26.9% vs. 17.8%; HR: 1.46; 95% CI: 0.92 to 2.30; p  0.11) and the composite outcome (27.6% vs.
19.5%; HR: 1.36; 95% CI: 0.87 to 2.12; p  0.18) favored CABG in patients with high-risk SYNTAX scores (inter-
action p  0.047 for death, interaction p  0.08 for composite outcome). Patients undergoing CABG consis-
tently had lower rates of target vessel revascularization.
Conclusions According to the complexity of concomitant coronary disease, there were differential treatment effects on long-
term mortality in patients with unprotected LMCA disease who received DES or underwent CABG. (J Am Coll
Cardiol 2011;57:2152–9) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.033Over the past few years, revascularization of patients with
significant coronary artery disease (CAD) has markedly
improved because of advances in both coronary artery bypass
grafting (CABG) and percutaneous coronary intervention
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ity (1,2). In particular, PCI involving drug-eluting stents
(DES) is increasingly used to treat complex CAD, such as
unprotected left main coronary artery (LMCA) disease, for
which CABG has been regarded historically as the treat-
ment of choice (3).
The choice of PCI or CABG for treatment of LMCA
disease or multivessel CAD depends on several clinical and
anatomical features, making optimal patient selection cru-
cial in determining the appropriate treatment and in achiev-
ing favorable long-term outcomes (4). Among these factors,
observational comparisons of CABG and PCI suggest a
strong relation between the extent of atherosclerotic CAD
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outcomes (5–11). However, in these studies, only a crude
proxy of atherosclerotic disease burden (i.e., the number of
disease vessels or involvement of specific disease location)
has been used, and therefore significant interaction between
the extent of atherosclerosis and treatment effect was
underestimated.
We previously reported that PCI with stenting showed
similar rates of safety outcomes, but inferior rates of efficacy
outcomes, compared with CABG in patients with unpro-
tected LMCA disease (12). However, the lack of informa-
tion to measure the extent of atherosclerosis would act as
important unmeasured confounders, and it could penalize
the apparent long-term benefits of surgery over PCI. Re-
cently, a detailed angiographic scoring system (SYNTAX
[Synergy Between PCI With Taxus and Cardiac Surgery]
score) to reflect complexity of CAD has been developed and
validated in several cohorts of patients with atherosclerotic
coronary disease (13–17).
In this study, to determine whether atherosclerotic
disease burden may influence the treatment choice and,
importantly, may also be linked to long-term outcomes,
we compared the relative treatment effects of PCI or
CABG for unprotected LMCA disease according to a
more detailed measure of extent of disease, such as the
SYNTAX score.
Methods
Study group and design. The MAIN-COMPARE (Re-
vascularization for Unprotected Left Main Coronary Artery
Stenosis: Comparison of Percutaneous Coronary Angio-
plasty Versus Surgical Revascularization) study enrolled
patients with unprotected LMCA stenosis who underwent
CABG or PCI as the index procedure at 12 major cardiac
centers in Korea between January 2000 and June 2006 (18).
From January 2000 through May 2003, coronary stenting
was performed exclusively with bare-metal stents, whereas
from May 2003 through June 2006, DES were used
exclusively. Because the SYNTAX score was developed in
the DES era, as an integral part of the SYNTAX trial
design, and methods of stent implantation have evolved
from the bare-metal stent era to the DES era with an
attempt to fully cover the diseased segments, we included
only the post-DES cohort (wave 2 of the registry; DES vs.
concurrent CABG between May 2003 and June 2006)
among the overall cohort for these analyses. The details of
the overall cohort and a separate cohort from bare-metal
stents to DES have been described previously (12). Patients
who had prior CABG, those who underwent concomitant
valvular or aortic surgery, and those who had ST-segment
elevation myocardial infarction (MI) or presented with
cardiogenic shock were excluded. The local ethics com-
mittee at each hospital approved the use of clinical data
for this study, and all patients provided written informed
consent.Patients underwent PCI, in-
stead of CABG, because of ei-
ther patient or physician prefer-
ence or the high risk associated
with CABG. Methods of stent
implantation for patients with
LMCA disease have been de-
scribed previously (19,20). All
procedures were performed using
standard interventional tech-
niques. Antiplatelet therapy and
periprocedural anticoagulation
followed standard regimens. Af-
ter the procedure, patients were
prescribed aspirin indefinitely
and clopidogrel for at least 6
months, regardless of DES type. Surgical revascularization
was performed using standard bypass techniques (21).
Complete revascularization was performed when possible
using arterial conduits or saphenous vein grafts. Clinical
follow-up after PCI and after CABG was recommended at
1 month, 6 months, and 1 year and then annually thereafter.
For this analysis, the follow-up period extended through
October 30, 2009, to ensure that all patients had an
opportunity for at least 3 years and approximately up to 7
years of follow-up information.
The primary safety outcomes were death and the com-
posite of death, Q-wave MI, or stroke. The primary efficacy
outcome was target vessel revascularization (TVR). Death
was defined as death from any cause. Q-wave MI was
defined as documentation of a new abnormal Q-wave after
the index revascularization. Stroke, as indicated by neuro-
logical deficits, was confirmed by a neurologist on the basis
of imaging studies. TVR was defined as any repeat revas-
cularization in any left anterior descending coronary artery
or left circumflex coronary artery, as well as in the target
segment. All outcomes of interest were confirmed by source
documentation collected at each hospital and were centrally
adjudicated by an independent group of clinicians.
The SYNTAX score reflects a comprehensive anatomical
assessment, with higher scores indicating more complex
CAD. As previously defined (13,14), we categorized study
patients according to the SYNTAX score; a low score was
defined as 22, an intermediate score as 23 to 32, and a
high score as 33. SYNTAX scores were calculated by the
independent angiographers blinded to patient information
and treatment types. The details of angiographic measure-
ments and the SYNTAX scoring algorithm at the core
laboratory have been described elsewhere (22).
Statistical analysis. For each category of the SYNTAX
score, patient characteristics pertaining to the index revas-
cularization, including demographic characteristics, the
presence or absence of a variety of clinical and coexisting
conditions, cardiac presentation, left ventricular function,
and lesion characteristics were compared between DES and
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CAD  coronary artery
disease
DES  drug-eluting stent(s)
LMCA  left main coronary
artery
MI  myocardial infarction
PCI  percutaneous
coronary intervention
TVR  target vessel
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DES Versus CABG for LMCA Disease May 24, 2011:2152–9nonparametric tests for continuous variables and the chi-
square or Fisher exact test for categorical variables. Five-year
cumulative incidence rates of clinical outcomes were esti-
mated using the Kaplan-Meier method and compared using
the log-rank test.
To reduce the impact of treatment selection bias and
potential confounding in an observational study, we
performed rigorous adjustment for differences in baseline
haracteristics of patients by use of weighted Cox proportional-
azards regression models using inverse-probability-of-
reatment weighting (23). With that technique, weights for
atients receiving CABG were the inverse of (1  propen-
ity score), and weights for patients receiving DES were the
nverse of the propensity score. Propensity scores were
stimated without regard to outcomes, using multiple logis-
ic regression analysis. A full nonparsimonious model was
eveloped that included all variables shown in Table 1.
odel discrimination was assessed using c-statistics, and
odel calibration was assessed using Hosmer-Lemeshow
tatistics. For each SYNTAX category (low, intermediate,
nd high risk), a separate propensity score for DES versus
ABG was derived. Interactions between the levels of
YNTAX score and treatment strategy were tested by the
ncorporation of formal interaction terms in the multivariate
Baseline Characteristics of Patients According to SYNTAX ScoreTable 1 Baseline Characteristics of Patients According to SYN
Variable
Low Risk (<22) (n  363)
DES
(n  302)
CABG
(n  61) p Value
Clinical characteristics
Age (yrs) 58.5 11.2 62.0 9.8 0.02
Men 202 (66.9%) 47 (77.0%) 0.12
Diabetes mellitus 76 (25.2%) 18 (29.5%) 0.48
Hypertension 132 (43.7%) 25 (41.0%) 0.70
Hyperlipidemia 93 (30.8%) 17 (27.9%) 0.65
Current smoker 76 (25.2%) 21 (34.4%) 0.14
Previous coronary angioplasty 59 (19.5%) 11 (18.0%) 0.79
Previous MI 18 (6.0%) 7 (11.5%) 0.12
Previous congestive heart failure 2 (0.7%) 0 (0%) 0.99
Chronic obstructive pulmonary
disease
8 (2.6%) 2 (3.3%) 0.68
Cerebrovascular disease 15 (5.0%) 2 (3.3%) 0.75
Peripheral vascular disease 3 (1.0%) 2 (3.3%) 0.20
Renal failure 5 (1.7%) 2 (3.3%) 0.33
Left ventricular ejection fraction (%) 61.9 9.1 59.3 10.6 0.08
Acute coronary syndromes 186 (61.6%) 38 (62.3%) 0.92
EuroSCORE 3.3 2.1 4.0 2.7 0.06
Angiographic characteristics
Distal LMCA bifurcation disease 151 (50.0%) 39 (63.9%) 0.047
Extent of diseased vessels 0.56*
LMCA only 113 (37.4%) 15 (24.6%)
LMCA plus single-vessel disease 87 (28.8%) 13 (21.3%)
LMCA plus double-vessel disease 57 (18.9%) 19 (31.1%)
LMCA plus triple-vessel disease 45 (14.9%) 14 (23.0%)
Right coronary artery disease 70 (23.2%) 21 (34.4%) 0.06
Data are expressed as mean  SD or n (%). *p value for trend.
CABG coronary artery bypass grafting; DES drug-eluting stents; EuroSCORE European System for
CI With Taxus and Cardiac Surgery.Cox model. Weighted Cox proportional-hazards regression
models and adjusted survival curves were constructed using
inverse probability weights (24). All statistical analyses were
performed using SAS version 9.1 (SAS Institute, Inc., Cary,
North Carolina), and a 2-sided p value of 0.05 was
considered to indicate statistical significance.
Results
Population. Between May 2003 and June 2006, 1,474
patients with unprotected LMCA disease were treated with
DES implantation (n  784) or CABG (n  690). During
he study enrollment period, the SYNTAX score algorithm
as not available for the physicians. A retrospective retrieval
f a baseline angiogram for a detailed measurement of the
YNTAX score was available in 1,146 patients (78%) of the
verall cohort (645 patients [82%] in the DES group and
01 patients [73%] in the CABG group). The mean
YNTAX score was significantly lower in the DES group
han in the CABG group (24.8  10.9 vs. 38.7  13.3,
 0.001).
Comparisons of the baseline characteristics between 2
reatment groups in each of the SYNTAX categories are
hown in Table 1. In each category of the SYNTAX score,
Score
ermediate Risk (23–32) (n  292) High Risk (>33) (n  491)
DES
 188)
CABG
(n  104) p Value
DES
(n  155)
CABG
(n  336) p Value
.9 10.1 62.8 9.4 0.08 66.1 10.2 64.5 8.8 0.09
9 (73.9%) 75 (72.1%) 0.74 112 (72.3%) 237 (70.5%) 0.70
4 (34.0%) 34 (32.7%) 0.82 69 (44.5%) 137 (40.8%) 0.44
9 (63.3%) 51 (49.0%) 0.02 95 (61.3%) 179 (53.3%) 0.10
8 (30.9%) 31 (29.8%) 0.85 64 (41.3%) 152 (45.2%) 0.41
3 (28.2%) 30 (28.8%) 0.91 24 (15.5%) 75 (22.3%) 0.08
5 (23.9%) 11 (10.6%) 0.005 36 (23.2%) 35 (10.4%) 0.001
2 (11.7%) 11 (10.6%) 0.77 18 (11.6%) 37 (11.0%) 0.84
4 (2.1%) 3 (2.9%) 0.70 5 (3.2%) 12 (3.6%) 0.85
5 (2.7%) 1 (1.0%) 0.43 3 (1.9%) 11 (3.3%) 0.56
2 (11.7%) 4 (3.8%) 0.02 17 (11.0%) 29 (8.6%) 0.41
4 (2.1%) 2 (1.9%) 0.99 4 (2.6%) 21 (6.3%) 0.09
6 (3.2%) 3 (2.9%) 0.99 9 (5.8%) 15 (4.5%) 0.52
.1 11.8 59.1 11.3 0.98 58.3 10.7 55.1 11.6 0.008
3 (60.1%) 71 (68.3%) 0.17 93 (60.0%) 268 (79.8%) 0.001
.1 2.4 4.1 2.1 0.84 4.3 2.6 4.8 2.3 0.04
3 (65.4%) 62 (59.6%) 0.32 100 (64.5%) 171 (50.9%) 0.005
0.16* 0.001*
8 (4.3%) 2 (1.9%) 6 (3.9%) 0 (0%)
9 (20.7%) 15 (14.4%) 16 (10.3%) 10 (3.0%)
2 (38.3%) 36 (34.6%) 50 (32.3%) 64 (19.0%)
9 (36.7%) 51 (49.0%) 83 (53.5%) 262 (78.0%)
9 (52.7%) 73 (70.2%) 0.004 100 (64.5%) 296 (88.1%) 0.001TAX
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May 24, 2011:2152–9 DES Versus CABG for LMCA Diseasethere were some imbalances of baseline clinical and angio-
graphic features between the 2 treatment groups with
statistical significance. Overall, with increasing SYNTAX
score, patients had higher risk clinical and angiographic
profiles.
Procedural characteristics of the study patients were as
follows: 1) among DES patients, 78% received sirolimus-
eluting stents and 22% received paclitaxel-eluting stents;
2) the mean number of stents implanted in a patient’s
LMCA lesions was 1.2  0.5, the mean total length of the
stents was 32.8  22.0 mm, and the mean stent diameter
was 3.4  0.2 mm; 3) among CABG patients, 46%
nderwent off-pump surgery; and 4) 96% underwent revas-
ularization of the left anterior descending coronary artery
ith an internal thoracic artery. Complete revascularization
as achieved in 64% of DES patients and 80% of CABG
atients.
utcomes. The median follow-up duration was 55.1
onths (interquartile range: 45.8 to 65.5 months) in the
verall patient group. Complete follow-up for major clinical
vents was obtained in 98.3% of the overall cohort (98.4%
or the DES group and 98.0% for the CABG group; p 
.57).
During 5 years of follow-up, the observed long-term rates
f death and the composite of death, Q-wave MI, or stroke
ere significantly lower in the DES group than in the
ABG group in patients with low SYNTAX scores
Table 2, Fig. 1). These safety outcomes were similar
etween the 2 treatment groups among patients with
ntermediate scores, but there was evidence of a nonsig-
ificant increase in the rate of safety outcomes associated
ith DES compared with CABG in patients with high
cores. The advantage of CABG was quite consistent for
VR.
After adjustment of baseline covariates using inverse-
robability-of-treatment weighting in each of the SYNTAX
HRs for Clinical Outcomes After DES Implantation Compared WithTable 2 HRs for Clinical Outcomes After DES Implantation Com
Outcome
n/Total Number
of Events
Cumula
Event R
at 5 Yrs
DES CABG DES
Low risk (SYNTAX score 22) 302 61
Death 17 9 6.1
Composite outcome‡ 18 9 6.4
TVR 37 3 13.4
Intermediate risk (SYNTAX score 23–32) 188 104
Death 15 8 8.3
Composite outcome‡ 18 10 9.9
TVR 31 2 19.2
High risk (SYNTAX score 33) 155 336
Death 35 64 26.9
Composite outcome‡ 36 70 27.6
TVR 25 12 18.8
*HRs are for the DES group relative to the CABG group. †p value for the treatment by covariate (S
outcome, interaction p  0.45 for TVR. ‡Death, Q-wave MI, or stroke.
CI  confidence interval; HR  hazard ratio; TVR  target vessel revascularization; other abbreviationcore categories, the adjusted hazard ratios for death and
erious composite outcomes favored DES treatment in
atients with low SYNTAX scores; in contrast, the adjusted
azard ratios for these safety outcomes favored CABG in
atients with high scores (Table 2, Fig. 2). When we
ssessed the effect on outcomes of treatment strategy and its
nteraction with SYNTAX score category, treatment effects
or death and composite outcomes, but not TVR, were
odified by the level of SYNTAX score (interaction p 
.047 for death, interaction p  0.08 for composite out-
ome, and interaction p  0.45 for TVR).
In the DES group, the rates of death and the composite
f death, Q-wave MI, or stroke were significantly increased
n patients with high SYNTAX scores compared with those
ith low or intermediate scores. In the CABG group,
owever, there was no uniform increase of safety outcomes
ccording to SYNTAX score.
In the overall population, the unadjusted risks for
eath and the composite of death, Q-wave MI, or stroke
ere significantly lower in the DES group than in the
ABG group, whereas the rate of TVR was significantly
igher in the DES group (Table 3). After adjustment of
he SYNTAX score, however, the 5-year risks for death and
he composite of death, Q-wave MI, or stroke were similar
n the 2 groups, but the adjusted risk for TVR was
onsistently higher with DES. Similar results were observed
ven after adjustments of the SYNTAX score and all
otentially explanatory factors for clinical outcomes.
iscussion
n this large-scale, multicenter study, which included 1,146
atients with unprotected LMCA disease, we found that
he adjusted long-term (5-year) risks for death and a
omposite of serious outcomes (death, Q-wave MI, or
troke) favored DES implantation over CABG in patients
, According to SYNTAX Score Category*d With CABG, According to SYNTAX Score Category*
Unadjusted
Adjusted by Inverse-Probability-of-
Treatment Weights†
HR (95% CI) p Value HR (95% CI) p Value
0.35 (0.16–0.79) 0.01 0.52 (0.21–1.28) 0.15
0.38 (0.17–0.84) 0.02 0.54 (0.22–1.34) 0.18
2.46 (0.76–7.98) 0.13 2.45 (0.75–8.08) 0.14
1.04 (0.44–2.45) 0.93 1.00 (0.38–2.62) 0.99
0.99 (0.46–2.15) 0.99 1.01 (0.42–2.45) 0.97
9.06 (2.17–37.84) 0.003 10.99 (2.56–47.33) 0.001
1.26 (0.83–1.90) 0.28 1.46 (0.92–2.30) 0.11
1.15 (0.77–1.73) 0.49 1.36 (0.87–2.12) 0.18
4.95 (2.49–9.86) 0.001 5.24 (2.28–12.06) 0.001
score category) interaction: interaction p  0.047 for death, interaction p  0.08 for compositeCABGpare
tive
ate
(%)
CABG
16.2
16.2
3.5
8.1
10.1
2.0
17.8
19.5
4.0
YNTAXs as in Table 1.
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DES Versus CABG for LMCA Disease May 24, 2011:2152–9with low risk for lesion complexity, as measured by the
SYNTAX score. Otherwise, the long-term risks for death
and the composite of serious outcomes favored CABG over
PCI in patients with high risk for lesion complexity. The
rates of TVR were consistently higher with DES than
CABG, regardless of SYNTAX score.
Compared with clinical trials, observational studies such
as ours may more accurately reflect “real-world” experience
in treating patients with LMCA disease. As with all
observational research, however, patient selection bias may
have a profound impact on outcomes, and there are many
considerations when one is choosing a treatment interven-
tion (4). Many patients with LMCA disease have concom-
itant multivessel disease. It is likely that patients with less
complex anatomy of atherosclerotic CAD tend to be more
Figure 1 Unadjusted Kaplan-Meier Survival Curves for Long-Ter
(A) Outcomes (death; a composite outcome of death, myocardial infarction [MI], o
Between PCI With Taxus and Cardiac Surgery) scores (22). (B) Outcomes in pati
SYNTAX scores (33). CABG  coronary artery bypass grafting; DES  drug-elutinoften referred for PCI, whereas those with more severedisease tend to be preferentially considered for bypass
surgery. Sometimes, patients with very complex angio-
graphic features have contraindications or are deemed inel-
igible for PCI. As such, because treatment type is consid-
erably correlated with the extent of atherosclerotic disease
burden, it is difficult to design a convincing observational
study that compares PCI with CABG for outcomes that are
related to disease burden. These factors therefore may cause
potential bias due to confounding by indication in compar-
ative clinical strategies studies (25).
Although several observational studies have attempted to
correct for atherosclerotic disease burden with covariates
such as the extent of diseased vessels (i.e., a count of
diseased vessels), this is a relatively generic concept that
lacks specificity to measure the extent of atherosclerotic
Year) Outcomes According to SYNTAX Score Category
e; and target-vessel revascularization) in patients with low SYNTAX (Synergy
ith intermediate SYNTAX scores (23 to 32). (C) Outcomes in patients with high
t(s).m (5-
r strok
ents w
g stenburden of disease. Therefore, adjustment for high-quality
2157JACC Vol. 57, No. 21, 2011 Park et al.
May 24, 2011:2152–9 DES Versus CABG for LMCA Diseaseanatomical data representing atherosclerotic burden might
minimize confounding by indication. The SYNTAX
score is a detailed anatomical scoring system that reflects
atherosclerotic disease burden. In our large cohort of
patients with unprotected LMCA disease, even after
comprehensive anatomical adjustment using the SYN-
TAX score, PCI with DES implantation showed similar
long-term safety outcomes, but inferior effectiveness
outcomes, compared with CABG.
Figure 2 Adjusted Survival Curves for Long-Term (5-Year) Outc
(A) Outcomes (death; a composite outcome of death, MI, or stroke; and target-ve
(B) Outcomes in patients with intermediate SYNTAX scores (23 to 32). (C) Outcom
Cox Proportional-Hazards Analyses of Time to Clinical Events AmonTable 3 Cox Proportional-Hazards Analyses of Time to Clinical
Outcome
Unadjusted
HR (95% CI) p Value
Death 0.63 (0.46–0.87) 0.006
Composite outcome‡ 0.61 (0.45–0.83) 0.002
TVR 4.40 (2.62–7.38) 0.001*HRs are for the DES group relative to the CABG group. †For a list of covariates, see Table 1. ‡Death, Q-
Abbreviations as in Tables 1 and 2.The recent SYNTAX trial reported that patients with the
least extensive CAD had better outcomes after DES treat-
ment, whereas patients with the most extensive disease had
better outcomes after CABG among those with 3-vessel or
LMCA disease (13,14). However, the follow-up in this
study was limited in duration, which may have resulted in a
disadvantage for CABG, because the apparent benefits of
surgery over PCI are usually not fully evident until 1 to 5
years after the procedure (26). Furthermore, the long-term
According to SYNTAX Score Category
vascularization) in patients with low SYNTAX scores (22).
patients with high SYNTAX scores (33). Abbreviations as in Figure 1.
erall Patient Group*ts Among Overall Patient Group*
djusted for SYNTAX Score
Adjusted for SYNTAX Score and
All Covariates†
(95% CI) p Value HR† (95% CI) p Value
0.74–1.56) 0.70 0.92 (0.63–1.35) 0.66
0.72–1.48) 0.85 0.91 (0.63–1.31) 0.62
3.04–9.44) 0.001 5.84 (3.26–10.48) 0.001omes
ssel re
es ing OvEven
A
HR†
1.08 (
1.03 (
5.35 (wave MI, or stroke.
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DES Versus CABG for LMCA Disease May 24, 2011:2152–9safety of DES has been questioned by recent reports
suggesting increased risks for late stent thrombosis, mortal-
ity, and MI (27,28). Therefore, very long-term assessment
of safety and efficacy of DES treatment, compared with
standard CABG, in a large cohort of patients with unpro-
tected LMCA disease is clinically essential. Consistent with
previous data and our hypothesis, we found an important
relationship between a more detailed measure of the com-
plexity of atherosclerotic CAD and long-term (5-year)
treatment effects. These results suggested that the extent of
atherosclerotic burden of CAD be considered an important
clinical factor affecting the choice between CABG and DES
and as a determinant for predicting long-term outcomes
after LMCA revascularization, suggesting an important role
of the SYNTAX score as an aid in decision making for
patient selection and risk stratification in clinical practice.
Study limitations. First, the inherent limitations of a
nonrandomized, registry study should be acknowledged.
The choice of revascularization was at the discretion of the
treating physician and/or patient. Despite rigorous adjust-
ment for selection bias and confounding with the inverse-
probability-of-treatment weighting method, hidden biases
or residual confounding may have affected the results.
Therefore, our findings should be confirmed or refuted
through large, randomized clinical trials with long-term
follow-up. Second, our analysis was underpowered to detect
significant differences in mortality and serious composite
outcomes. Nonsignificant trends for these outcomes might
have been significant with a larger cohort of patients. Third,
in the present analysis, SYNTAX scoring was performed
retrospectively and only in 78% of cases, introducing at least
the potential of an unmeasured bias. Finally, because this
study evaluated the first generation of DES, the direct
application of these findings to second-generation or next-
generation DES may be limited.
Conclusions
In patients with unprotected LMCA disease, according to
the anatomical complexity of concomitant CAD measured
by the SYNTAX score, PCI with DES compares favorably
with CABG for patients with a low burden of disease with
regard to serious safety outcomes (death or the composite of
death, Q-wave MI, or stroke). Conversely, CABG com-
pares favorably with PCI for patients with a high athero-
sclerotic burden of disease.
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